向中枢神经系统的治疗性给药

Therapeutic Delivery to Central Nervous System.

作者信息

Kunigelis Katherine E, Vogelbaum Michael A

机构信息

Department of Neuro-Oncology, Neuro-Oncology Program, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.

出版信息

Neurosurg Clin N Am. 2021 Apr;32(2):291-303. doi: 10.1016/j.nec.2020.12.004. Epub 2021 Feb 18.

DOI:10.1016/j.nec.2020.12.004

PMID:33781509

Abstract

Therapies for glioblastoma face several physiologic hurdles. The blood-brain barrier (BBB) and blood-brain-tumor barrier (BTB) present impediments to therapeutic delivery of drugs to the central nervous system. Strategies to disrupt or bypass the native BBB are necessary to deliver therapeutic agents. Techniques to bypass the BBB/BTB include implantable controlled-release polymer systems, intracavitary drug delivery, direct injection of viral vectors, and infusion via convection-enhanced delivery. Ideal methods and agents to accomplish the goal providing survival benefit are yet to be determined. Further development of methods to break down or bypass the BBB and BTB is necessary for patients with glioblastoma.

摘要

胶质母细胞瘤的治疗面临着几个生理障碍。血脑屏障（BBB）和血脑肿瘤屏障（BTB）阻碍了药物向中枢神经系统的治疗性递送。破坏或绕过天然血脑屏障的策略对于递送治疗剂是必要的。绕过血脑屏障/血脑肿瘤屏障的技术包括可植入控释聚合物系统、腔内给药、病毒载体直接注射以及通过对流增强递送进行输注。实现提供生存益处这一目标的理想方法和药物尚未确定。对于胶质母细胞瘤患者，进一步开发分解或绕过血脑屏障和血脑肿瘤屏障的方法是必要的。